Ãå±±½ûµØ

• For Print
• August 1, 2023

<Changes of Corporate Officers, effective August 1, 2023>

Reorganization of Deep Human Biology Learning (DHBL)

1. 1.  Integration of Alzheimer's Disease and Brain Health (ADBH) Clinical Development Functions

To maximize the value of launched products and accelerate the development of new drugs that will lead future growth of Eisai, and promote the efficiency of clinical research and development, the clinical functions of ADBH will be integrated into DHBL. Under the Chief Scientific Officer, a Chief Clinical Officer, a Neurology Clinical Lead, an Oncology Clinical Lead, and a Chief Clinical Science & Operations Officer will be appointed to ensure a smooth transition to the new structure of DHBL.

The Medical Affairs function of ADBH will be moved directly under the Chief Scientific Officer, and the Value & Access and Global Marketing functions will be placed directly under the Global Alzheimer's Disease Officer.

1. 2.  Reorganization of Clinical Development function (Clinical Evidence Generation Fulfillment)

Clinical Evidence Generation (CEG) Fulfillment, which is the function responsible for proving DHBL drug discovery concepts in clinical trials and obtaining regulatory approval, will be reorganized into the Clinical Development function, which is responsible for Clinical Research, Global Regulatory, etc., and the Clinical Science & Operations function, which consolidates biostatistical analysis, data science, clinical operations, etc. A Chief Clinical Science & Operations Officer will be appointed to oversee the common operational functions of clinical research and development in the Clinical Science and Operations function.

  　

&²Ô²ú²õ±è;〶Ä

Media Inquiries:

Public Relations Department,

Ãå±±½ûµØ.

+81-(0)3-3817-5120

〶Ä〶Ä

• Full text